Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4688)	7/1/1998 8:27:00 PM
From: billkirn	Read Replies (1) \| Respond to of 6136

Steve: Bought some IMNR after AGPH entry. Don't expect the results to be conclusive. IMO the data should be good and suggestive towards a possible cure over time with Remune, however it will take years for this to be proven out. Let's hope the data is good enough to get FDA blessing while monitoring its progress over the years. I think Peter J. believes it has a good chance to work. This may encourage asymptomatic(?) folks to start treatment sooner with a real possibility of a cure in a few years. Data won't be conclusive, but encouraging, will leave room for interpretation and uncertainty and the stock price will reflect it in some way... Bill